Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Overexpression of prolyl endopeptidase (PEP) activity in the brain was found to be linked with neurodegenerative disorders, and the memory loss caused by amnesic compounds can be restored by PEP inhibitors. In the current intervention, the PEP inhibitory activity of trans-anethole ((E)-1-Methoxy-4-(1-propenyl)benzene), an essential oil that is naturally occurring in Illicium verum (star anise) has been assessed. More specifically, the present invention relates to finding of a potent inhibitor of prolyl endopeptidase (Trans-Anethole ((E)-1-Methoxy-4-(1-propenyl)benzene).

Overexpression of prolyl endopeptidase (PEP) activity in the brain was found to be linked with neurodegenerative disorders, and the memory loss caused by amnesic compounds can be restored by PEP inhibitors. In the current intervention, the PEP inhibitory activity of trans-anethole ((E)-1-Methoxy-4-(1-propenyl)benzene), an essential oil that is naturally occurring in Illicium verum (star anise) has been assessed. More specifically, the present invention relates to finding of a potent inhibitor of prolyl endopeptidase (Trans-Anethole ((E)-1-Methoxy-4-(1-propenyl)benzene).

Provided herein are compositions, systems, articles of manufacture, and methods of treating a subject with: i) an APE2 inhibitor, and ii) a drug agent that causes increased expression of APE2 in said subject. In certain embodiments, the drug agent is Cisplatin or similar drug.

Provided herein are compositions, systems, articles of manufacture, and methods of treating a subject with: i) an APE2 inhibitor, and ii) a drug agent that causes increased expression of APE2 in said subject. In certain embodiments, the drug agent is Cisplatin or similar drug.

A composition comprising at least one amino acid, (ii) a controlled release lipid matrix, and optionally (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient and a related method for the treatment of amino acid supply or protein deficiency in a monogastric subject, preferably a human subject or a pig, are disclosed as well as a feed or feed additive comprising the composition for a monogastric animal, preferably a pig.

A composition comprising at least one amino acid, (ii) a controlled release lipid matrix, and optionally (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient and a related method for the treatment of amino acid supply or protein deficiency in a monogastric subject, preferably a human subject or a pig, are disclosed as well as a feed or feed additive comprising the composition for a monogastric animal, preferably a pig.